{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:43:59Z","timestamp":1787510639866,"version":"build-2736575974"},"reference-count":244,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T00:00:00Z","timestamp":1735084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T00:00:00Z","timestamp":1735084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2022\/47\/D\/NZ7\/03212"],"award-info":[{"award-number":["2022\/47\/D\/NZ7\/03212"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2022\/47\/D\/NZ7\/03212"],"award-info":[{"award-number":["2022\/47\/D\/NZ7\/03212"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2022\/47\/D\/NZ7\/03212"],"award-info":[{"award-number":["2022\/47\/D\/NZ7\/03212"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2022\/47\/D\/NZ7\/03212"],"award-info":[{"award-number":["2022\/47\/D\/NZ7\/03212"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","award":["GAR- O_STARS_MUR22_01"],"award-info":[{"award-number":["GAR- O_STARS_MUR22_01"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CN00000041"],"award-info":[{"award-number":["CN00000041"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CN00000041"],"award-info":[{"award-number":["CN00000041"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CN00000041"],"award-info":[{"award-number":["CN00000041"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"Narodowe Centrum Bada\u0144 i Rozwoju","doi-asserted-by":"publisher","award":["0258\/L-14\/2023"],"award-info":[{"award-number":["0258\/L-14\/2023"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Public Health NIH \u2013 National Research Institute","award":["BW-3\/2024"],"award-info":[{"award-number":["BW-3\/2024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Decades of basic and translational research have led to a momentum shift in dissecting the relationship between immune cells and cancer. This culminated in the emergence of breakthrough immunotherapies that paved the way for oncologists to manage certain hard-to-treat cancers. The application of high-throughput techniques of genomics, transcriptomics, and proteomics was conclusive in making and expediting the manufacturing process of cancer vaccines. Using the latest research technologies has also enabled scientists to interpret complex and multiomics data of the tumour mutanome, thus identifying new tumour-specific antigens to design new generations of cancer vaccines with high specificity and long-term efficacy. Furthermore, combinatorial regimens of cancer vaccines with immune checkpoint inhibitors have offered new therapeutic approaches and demonstrated impressive efficacy in cancer patients over the last few years. In the present review, we summarize the current state of cancer vaccines, including their potential therapeutic effects and the limitations that hinder their effectiveness. We highlight the current efforts to mitigate these limitations and highlight ongoing clinical trials. Finally, a special focus will be given to the latest milestones expected to transform the landscape of cancer therapy and nurture hope among cancer patients.<\/jats:p>","DOI":"10.1007\/s10238-024-01541-7","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T07:38:19Z","timestamp":1735112299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cancer vaccines: an update on recent achievements and prospects for cancer therapy"],"prefix":"10.1007","volume":"25","author":[{"given":"Arezki","family":"Chekaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Gad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Staniszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Chiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Pancer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Gryciuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Salmaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caliceti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Masny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Wieczorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Pesonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Kuryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,25]]},"reference":[{"key":"1541_CR1","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","volume":"21","author":"JS Brown","year":"2023","unstructured":"Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the definition of cancer. Mol Cancer Res. 2023;21:1142\u20137.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"1541_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, Bray F. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778\u201389. https:\/\/doi.org\/10.1002\/ijc.33588.","journal-title":"Int J Cancer"},{"key":"1541_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1541_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21873\/anticanres.14746","volume":"41","author":"KS Rallis","year":"2021","unstructured":"Rallis KS, Lai Yau TH, Sideris M. Chemoradiotherapy in cancer treatment: rationale and clinical applications. Anticancer Res. 2021;41:1\u20137.","journal-title":"Anticancer Res"},{"key":"1541_CR5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7:258.","journal-title":"Signal Transduct Target Ther"},{"key":"1541_CR6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.radonc.2018.06.026","volume":"129","author":"V Batumalai","year":"2018","unstructured":"Batumalai V, Shafiq J, Gabriel G, Hanna TP, Delaney GP, Barton M. Impact of radiotherapy underutilisation measured by survival shortfall, years of potential life lost and disability-adjusted life years lost in New South Wales. Aust Radiother Oncol. 2018;129:191\u20135.","journal-title":"Aust Radiother Oncol"},{"key":"1541_CR7","doi-asserted-by":"crossref","first-page":"205031212110343","DOI":"10.1177\/20503121211034366","volume":"9","author":"DT Debela","year":"2021","unstructured":"Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK, Manyazewal T. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 2021;9:20503121211034370.","journal-title":"SAGE Open Med"},{"key":"1541_CR8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40169-017-0175-0","volume":"6","author":"S Tran","year":"2017","unstructured":"Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017;6:44.","journal-title":"Clin Transl Med"},{"key":"1541_CR9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-032414-112043","volume":"33","author":"SR Woo","year":"2015","unstructured":"Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015;33:445\u201374.","journal-title":"Annu Rev Immunol"},{"key":"1541_CR10","first-page":"37","volume":"19","author":"PDMG Netea","year":"2023","unstructured":"Netea PDMG. I. IDC Key-note lecture: trained immunity: a memory for innate host defense. J Stem Cells Regen Med. 2023;19:37\u20139.","journal-title":"J Stem Cells Regen Med"},{"key":"1541_CR11","unstructured":"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279364\/."},{"key":"1541_CR12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807\u201321.","journal-title":"Cell Mol Immunol"},{"key":"1541_CR13","doi-asserted-by":"crossref","first-page":"9903","DOI":"10.1007\/s11033-022-07525-8","volume":"49","author":"SL Gupta","year":"2022","unstructured":"Gupta SL, Basu S, Soni V, Jaiswal RK. Immunotherapy: an alternative promising therapeutic approach against cancers. Mol Biol Rep. 2022;49:9903\u201313.","journal-title":"Mol Biol Rep"},{"key":"1541_CR14","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","volume":"15","author":"S Ma","year":"2019","unstructured":"Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z, Qian Q. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15:2548\u201360.","journal-title":"Int J Biol Sci"},{"key":"1541_CR15","first-page":"13","volume":"20","author":"T Tripathi","year":"2023","unstructured":"Tripathi T. Advances in vaccines: revolutionizing disease prevention. Sci Rep. 2023;20:13.","journal-title":"Sci Rep"},{"key":"1541_CR16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s43556-022-00098-9","volume":"3","author":"Y Tian","year":"2022","unstructured":"Tian Y, Hu D, Li Y, Yang L. Development of therapeutic vaccines for the treatment of diseases. Mol Biomed. 2022;3:40.","journal-title":"Mol Biomed"},{"key":"1541_CR17","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1093\/cid\/ciab079","volume":"73","author":"SM Moghadas","year":"2021","unstructured":"Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, Meyers LA, Neuzil KM, Langley JM, Fitzpatrick MC, Galvani AP. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clin Infect Dis. 2021;73:2257\u201364.","journal-title":"Clin Infect Dis"},{"key":"1541_CR18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cell.2020.09.040","volume":"183","author":"A Iwasaki","year":"2020","unstructured":"Iwasaki A, Omer SB. Why and how vaccines work. Cell. 2020;183:290\u20135.","journal-title":"Cell"},{"key":"1541_CR19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri1150","volume":"3","author":"OJ Finn","year":"2003","unstructured":"Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003;3:630\u201341.","journal-title":"Nat Rev Immunol"},{"key":"1541_CR20","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56:2188\u2013205.","journal-title":"Immunity"},{"key":"1541_CR21","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4049\/jimmunol.1403134","volume":"194","author":"JM Tran Janco","year":"2015","unstructured":"Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol. 2015;194:2985\u201391.","journal-title":"J Immunol"},{"key":"1541_CR22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1074-7613(03)00175-4","volume":"19","author":"AA Itano","year":"2003","unstructured":"Itano AA, McSorley SJ, Reinhardt RL, Ehst BD, Ingulli E, Rudensky AY, Jenkins MK. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity. 2003;19:47\u201357.","journal-title":"Immunity"},{"key":"1541_CR23","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1084\/jem.143.5.1283","volume":"143","author":"MJ Bevan","year":"1976","unstructured":"Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976;143:1283\u20138.","journal-title":"J Exp Med"},{"key":"1541_CR24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.immuni.2008.08.004","volume":"29","author":"CJ Melief","year":"2008","unstructured":"Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008;29:372\u201383.","journal-title":"Immunity"},{"key":"1541_CR25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fimmu.2013.00483","volume":"4","author":"G Schiavoni","year":"2013","unstructured":"Schiavoni G, Mattei F, Gabriele L. Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response. Front Immunol. 2013;4:483.","journal-title":"Front Immunol"},{"key":"1541_CR26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fimmu.2014.00174","volume":"5","author":"OA Haabeth","year":"2014","unstructured":"Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B. How Do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front Immunol. 2014;5:174.","journal-title":"Front Immunol"},{"key":"1541_CR27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, G\u00f6genur I. Cytotoxic CD8. Br J Cancer. 2021;124:359\u201367.","journal-title":"Br J Cancer"},{"key":"1541_CR28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00281-016-0587-8","volume":"39","author":"MC Takenaka","year":"2017","unstructured":"Takenaka MC, Quintana FJ. Tolerogenic dendritic cells. Semin Immunopathol. 2017;39:113\u201320.","journal-title":"Semin Immunopathol"},{"key":"1541_CR29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15:28.","journal-title":"J Hematol Oncol"},{"key":"1541_CR30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"1541_CR31","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"1541_CR32","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"1541_CR33","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","volume":"126","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Plimack ER, Procopio G, McDermott DF, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126:4156\u201367.","journal-title":"Cancer"},{"key":"1541_CR34","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/pharmaceutics15041143","volume":"15","author":"SS Said","year":"2023","unstructured":"Said SS, Ibrahim WN. Cancer resistance to immunotherapy: comprehensive insights with future perspectives. Pharmaceutics. 2023;15:1143.","journal-title":"Pharmaceutics"},{"key":"1541_CR35","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1158\/1078-0432.CCR-14-0879","volume":"20","author":"TE Angell","year":"2014","unstructured":"Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014;20:6034\u201344.","journal-title":"Clin Cancer Res"},{"key":"1541_CR36","doi-asserted-by":"crossref","first-page":"1190333","DOI":"10.3389\/fimmu.2023.1190333","volume":"14","author":"J Han","year":"2023","unstructured":"Han J, Wu M, Liu Z. Dysregulation in IFN-gamma signaling and response: the barricade to tumor immunotherapy. Front Immunol. 2023;14:1190333.","journal-title":"Front Immunol"},{"key":"1541_CR37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41540-023-00322-4","volume":"9","author":"E Yakubovich","year":"2023","unstructured":"Yakubovich E, Cook DP, Rodriguez GM, Vanderhyden BC. Mesenchymal ovarian cancer cells promote CD8. NPJ Syst Biol Appl. 2023;9:61.","journal-title":"NPJ Syst Biol Appl"},{"key":"1541_CR38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/intimm\/dxw014","volume":"28","author":"S Spranger","year":"2016","unstructured":"Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol. 2016;28:383\u201391.","journal-title":"Int Immunol"},{"key":"1541_CR39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2007.06.009","volume":"17","author":"JM Reiman","year":"2007","unstructured":"Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol. 2007;17:275\u201387.","journal-title":"Semin Cancer Biol"},{"key":"1541_CR40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51:27\u201341.","journal-title":"Immunity"},{"key":"1541_CR41","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41419-018-0465-5","volume":"9","author":"P Zheng","year":"2018","unstructured":"Zheng P, Luo Q, Wang W, Li J, Wang T, Wang P, Chen L, Zhang P, Chen H, Liu Y, et al. Tumor-associated macrophages-derived exosomes promote the migration of gastric cancer cells by transfer of functional apolipoprotein E. Cell Death Dis. 2018;9:434.","journal-title":"Cell Death Dis"},{"key":"1541_CR42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.molonc.2007.10.003","volume":"1","author":"EY Lin","year":"2007","unstructured":"Lin EY, Li JF, Bricard G, Wang W, Deng Y, Sellers R, Porcelli SA, Pollard JW. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol. 2007;1:288\u2013302.","journal-title":"Mol Oncol"},{"key":"1541_CR43","doi-asserted-by":"crossref","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","volume":"6","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6:e1792.","journal-title":"Cell Death Dis"},{"key":"1541_CR44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.crimmu.2021.08.002","volume":"2","author":"T Sarkar","year":"2021","unstructured":"Sarkar T, Dhar S, Sa G. Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape. Curr Res Immunol. 2021;2:132\u201341.","journal-title":"Curr Res Immunol"},{"issue":"6","key":"1541_CR45","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.3390\/cancers12061660","volume":"12","author":"S Feola","year":"2020","unstructured":"Feola S, Chiaro J, Martins B, Cerullo V. Uncovering the tumor antigen landscape: what to know about the discovery process. Cancers. 2020;12(6):1660. https:\/\/doi.org\/10.3390\/cancers12061660.","journal-title":"Cancers"},{"key":"1541_CR46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","volume":"4","author":"RE Hollingsworth","year":"2019","unstructured":"Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7.","journal-title":"NPJ Vaccines"},{"key":"1541_CR47","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18:168\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1541_CR48","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/vaccines8040615","volume":"8","author":"L Buonaguro","year":"2020","unstructured":"Buonaguro L, Tagliamonte M. Selecting target antigens for cancer vaccine development. Vaccines. 2020;8(4):615. https:\/\/doi.org\/10.3390\/vaccines8040615.","journal-title":"Vaccines"},{"key":"1541_CR49","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1038\/s41598-020-62244-z","volume":"10","author":"KC Han","year":"2020","unstructured":"Han KC, Park D, Ju S, Lee YE, Heo SH, Kim YA, Lee JE, Lee Y, Park KH, Park SH, et al. Streamlined selection of cancer antigens for vaccine development through integrative multi-omics and high-content cell imaging. Sci Rep. 2020;10:5885.","journal-title":"Sci Rep"},{"key":"1541_CR50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","volume":"19","author":"CC Smith","year":"2019","unstructured":"Smith CC, Selitsky SR, Chai S, Armistead PM, Vincent BG, Serody JS. Alternative tumour-specific antigens. Nat Rev Cancer. 2019;19:465\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1541_CR51","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(20)30524-6","volume":"21","author":"C Porras","year":"2020","unstructured":"Porras C, Tsang SH, Herrero R, Guill\u00e9n D, Darragh TM, Stoler MH, Hildesheim A, Wagner S, Boland J, Lowy DR, et al. Efficacy of the bivalent HPV vaccine against HPV 16\/18-associated precancer long-term follow-up results from the costa rica vaccine trial. Lancet Oncol. 2020;21(12):1643\u201352.","journal-title":"Lancet Oncol"},{"key":"1541_CR52","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1016\/j.vaccine.2022.10.022","volume":"40","author":"Y Shu","year":"2022","unstructured":"Shu Y, Yu Y, Ji Y, Zhang L, Li Y, Qin H, Huang Z, Ou Z, Huang M, Shen Q, et al. Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20\u201345 years: a randomized, blinded, controlled with Gardasil (type 6\/11\/16\/18), phase III non-inferiority clinical trial. Vaccine. 2022;40:6947\u201355.","journal-title":"Vaccine"},{"key":"1541_CR53","doi-asserted-by":"crossref","first-page":"215652","DOI":"10.1016\/j.canlet.2022.215652","volume":"536","author":"M Cao","year":"2022","unstructured":"Cao M, Fan J, Lu L, Fan C, Wang Y, Chen T, Zhang S, Yu Y, Xia C, Lu J, et al. Long term outcome of prevention of liver cancer by hepatitis B vaccine: results from an RCT with 37 years. Cancer Lett. 2022;536:215652.","journal-title":"Cancer Lett"},{"key":"1541_CR54","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-19-1513","volume":"26","author":"YJ Choi","year":"2020","unstructured":"Choi YJ, Hur SY, Kim TJ, Hong SR, Lee JK, Cho CH, Park KS, Woo JW, Sung YC, Suh YS, Park JS. A phase II, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3. Clin Cancer Res. 2020;26:1616\u201323.","journal-title":"Clin Cancer Res"},{"key":"1541_CR55","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515:572\u20136.","journal-title":"Nature"},{"key":"1541_CR56","doi-asserted-by":"crossref","first-page":"931612","DOI":"10.3389\/fimmu.2022.931612","volume":"13","author":"C Jiang","year":"2022","unstructured":"Jiang C, Li J, Zhang W, Zhuang Z, Liu G, Hong W, Li B, Zhang X, Chao CC. Potential association factors for developing effective peptide-based cancer vaccines. Front Immunol. 2022;13:931612.","journal-title":"Front Immunol"},{"key":"1541_CR57","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.21037\/tcr-21-2798","volume":"11","author":"HH Lee","year":"2022","unstructured":"Lee HH, Hong SH, Rhee JH, Lee SE. Optimal long peptide for flagellin-adjuvanted HPV E7 cancer vaccine to enhance tumor suppression in combination with anti-PD-1. Transl Cancer Res. 2022;11:1595\u2013602.","journal-title":"Transl Cancer Res"},{"key":"1541_CR58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13073-017-0439-8","volume":"9","author":"CJM Melief","year":"2017","unstructured":"Melief CJM, Kessler JH. Novel insights into the HLA class I immunopeptidome and T-cell immunosurveillance. Genome Med. 2017;9:44.","journal-title":"Genome Med"},{"key":"1541_CR59","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1074\/jbc.M809456200","volume":"284","author":"H Zhang","year":"2009","unstructured":"Zhang H, Hong H, Li D, Ma S, Di Y, Stoten A, Haig N, Di Gleria K, Yu Z, Xu XN, et al. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells. J Biol Chem. 2009;284:9184\u201391.","journal-title":"J Biol Chem"},{"key":"1541_CR60","first-page":"1033","volume":"38","author":"MS Bijker","year":"2008","unstructured":"Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged. DC-focused antigen presentation Eur J Immunol. 2008;38:1033\u201342.","journal-title":"DC-focused antigen presentation Eur J Immunol"},{"key":"1541_CR61","doi-asserted-by":"crossref","first-page":"114142","DOI":"10.1016\/j.addr.2022.114142","volume":"183","author":"YL Vishweshwaraiah","year":"2022","unstructured":"Vishweshwaraiah YL, Dokholyan NV. Toward rational vaccine engineering. Adv Drug Deliv Rev. 2022;183:114142.","journal-title":"Adv Drug Deliv Rev"},{"key":"1541_CR62","doi-asserted-by":"crossref","first-page":"633776","DOI":"10.3389\/fcell.2021.633776","volume":"9","author":"F Qin","year":"2021","unstructured":"Qin F, Xia F, Chen H, Cui B, Feng Y, Zhang P, Chen J, Luo M. A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: from basic principles to current applications. Front Cell Dev Biol. 2021;9:633776.","journal-title":"Front Cell Dev Biol"},{"key":"1541_CR63","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1016\/j.vaccine.2016.09.062","volume":"34","author":"SHT Jorritsma","year":"2016","unstructured":"Jorritsma SHT, Gowans EJ, Grubor-Bauk B, Wijesundara DK. Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines. Vaccine. 2016;34:5488\u201394.","journal-title":"Vaccine"},{"key":"1541_CR64","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","volume":"13","author":"JJ Suschak","year":"2017","unstructured":"Suschak JJ, Williams JA, Schmaljohn CS. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Hum Vaccin Immunother. 2017;13:2837\u201348.","journal-title":"Hum Vaccin Immunother"},{"key":"1541_CR65","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000053994","volume":"43","author":"S Manam","year":"2000","unstructured":"Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ, Harper LB, Griffiths TG, Niu Z, Denisova L, Follmer TT, et al. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology. 2000;43:273\u201381.","journal-title":"Intervirology"},{"key":"1541_CR66","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1535-7163.MCT-15-0742","volume":"15","author":"MO Diniz","year":"2016","unstructured":"Diniz MO, Sales NS, Silva JR, Ferreira LC. Protection against HPV-16-associated tumors requires the activation of CD8+ effector memory T cells and the control of myeloid-derived suppressor cells. Mol Cancer Ther. 2016;15:1920\u201330.","journal-title":"Mol Cancer Ther"},{"key":"1541_CR67","first-page":"A481","volume":"9","author":"M Yarchoan","year":"2021","unstructured":"Yarchoan M, Gane E, Marron T, Rochestie S, Cooch N, Peters J, Csiki I, Perales-Puchalt A, Sardesai N. 453 Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma. J Immunother Cancer. 2021;9:A481\u2013A481.","journal-title":"J Immunother Cancer"},{"key":"1541_CR68","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/1078-0432.CCR-17-2033","volume":"24","author":"EK Duperret","year":"2018","unstructured":"Duperret EK, Trautz A, Ammons D, Perales-Puchalt A, Wise MC, Yan J, Reed C, Weiner DB. Alteration of the tumor stroma using a consensus DNA vaccine targeting fibroblast activation protein (FAP) synergizes with antitumor vaccine therapy in mice. Clin Cancer Res. 2018;24:1190\u2013201.","journal-title":"Clin Cancer Res"},{"key":"1541_CR69","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.biopha.2017.03.015","volume":"90","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Wei Z, Yang H, Li X, Wang Q, Wang L, Li S. Enhance the anti-renca carcinoma effect of a DNA vaccine targeting G250 gene by co-expression with cytotoxic T-lymphocyte associated antigen-4(CTLA-4). Biomed Pharmacother. 2017;90:147\u201352.","journal-title":"Biomed Pharmacother"},{"key":"1541_CR70","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","volume":"386","author":"CL Trimble","year":"2015","unstructured":"Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386:2078\u201388.","journal-title":"Lancet"},{"key":"1541_CR71","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.4161\/21645515.2014.980686","volume":"10","author":"B Yang","year":"2014","unstructured":"Yang B, Jeang J, Yang A, Wu TC, Hung CF. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10:3153\u201364.","journal-title":"Hum Vaccin Immunother"},{"key":"1541_CR72","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4049\/jimmunol.142.5.1482","volume":"142","author":"GS Gilkeson","year":"1989","unstructured":"Gilkeson GS, Grudier JP, Karounos DG, Pisetsky DS. Induction of anti-double stranded DNA antibodies in normal mice by immunization with bacterial DNA. J Immunol. 1989;142:1482\u20136.","journal-title":"J Immunol"},{"issue":"8932","key":"1541_CR73","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/S0140-6736(94)90776-5","volume":"344","author":"D Lilic","year":"1994","unstructured":"Lilic D, Ghosh SK. Liver dysfunction and DNA antibodies after hepatitis B vaccination. Lancet. 1994;344(8932):1292\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(94)90776-5.","journal-title":"Lancet"},{"key":"1541_CR74","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/0961203311429318","volume":"21","author":"Y Zafrir","year":"2012","unstructured":"Zafrir Y, Agmon-Levin N, Paz Z, Shilton T, Shoenfeld Y. Autoimmunity following hepatitis B vaccine as part of the spectrum of \u201cAutoimmune (Auto-inflammatory) Syndrome induced by Adjuvants\u201d (ASIA): analysis of 93 cases. Lupus. 2012;21:146\u201352.","journal-title":"Lupus"},{"key":"1541_CR75","doi-asserted-by":"crossref","first-page":"1029069","DOI":"10.3389\/fimmu.2022.1029069","volume":"13","author":"YL Vishweshwaraiah","year":"2022","unstructured":"Vishweshwaraiah YL, Dokholyan NV. mRNA vaccines for cancer immunotherapy. Front Immunol. 2022;13:1029069.","journal-title":"Front Immunol"},{"key":"1541_CR76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","volume":"20","author":"JD Beck","year":"2021","unstructured":"Beck JD, Reidenbach D, Salomon N, Sahin U, T\u00fcreci \u00d6, Vormehr M, Kranz LM. mRNA therapeutics in cancer immunotherapy. Mol Cancer. 2021;20:69.","journal-title":"Mol Cancer"},{"key":"1541_CR77","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/14760584.2023.2232450","volume":"22","author":"MI Mohamad Razif","year":"2023","unstructured":"Mohamad Razif MI, Nizar N, Zainal Abidin NH, Muhammad Ali SN, Wan Zarimi WNN, Khotib J, Susanti D, Mohd Jailani MT, Taher M. Emergence of mRNA vaccines in the management of cancer. Expert Rev Vaccines. 2023;22:629\u201342.","journal-title":"Expert Rev Vaccines"},{"key":"1541_CR78","first-page":"71","volume":"440","author":"C Zeng","year":"2022","unstructured":"Zeng C, Zhang C, Walker PG, Dong Y. Formulation and delivery technologies for mRNA vaccines. Curr Top Microbiol Immunol. 2022;440:71\u2013110.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"12","key":"1541_CR79","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3390\/vaccines11121737","volume":"11","author":"Ryo Okuyama","year":"2023","unstructured":"Okuyama Ryo. mRNA and adenoviral vector vaccine platforms utilized in COVID-19 vaccines: technologies, ecosystem, and future directions. Vaccines. 2023;11(12):1737. https:\/\/doi.org\/10.3390\/vaccines11121737.","journal-title":"Vaccines"},{"key":"1541_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-03119-x","author":"Elie Dolgin","year":"2023","unstructured":"Dolgin Elie, Ledford Heidi. mRNA COVID vaccines saved lives and won a Nobel\u2014what\u2019s next for the technology? Nature. 2023. https:\/\/doi.org\/10.1038\/d41586-023-03119-x.","journal-title":"Nature"},{"key":"1541_CR81","doi-asserted-by":"crossref","first-page":"1246682","DOI":"10.3389\/fimmu.2023.1246682","volume":"14","author":"B Wang","year":"2023","unstructured":"Wang B, Pei J, Xu S, Liu J, Yu J. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. Front Immunol. 2023;14:1246682.","journal-title":"Front Immunol"},{"key":"1541_CR82","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585:107\u201312.","journal-title":"Nature"},{"key":"1541_CR83","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350.","journal-title":"Nature"},{"key":"1541_CR84","first-page":"e16635","volume":"13","author":"A Saleh","year":"2021","unstructured":"Saleh A, Qamar S, Tekin A, Singh R, Kashyap R. Vaccine development throughout history. Cureus. 2021;13:e16635.","journal-title":"Cureus"},{"key":"1541_CR85","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, Wang T, Yan F, Yang S, Xia X. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023;8:149.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"1541_CR86","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/vaccines8040680","volume":"8","author":"SM Vrba","year":"2020","unstructured":"Vrba SM, Kirk NM, Brisse ME, Liang Y, Ly H. Development and applications of viral vectored vaccines to combat zoonotic and emerging public health threats. Vaccines. 2020;8(4):680. https:\/\/doi.org\/10.3390\/vaccines8040680.","journal-title":"Vaccines"},{"key":"1541_CR87","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2009.130","volume":"17","author":"MO Lasaro","year":"2009","unstructured":"Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol Ther. 2009;17:1333\u20139.","journal-title":"Mol Ther"},{"key":"1541_CR88","first-page":"67","volume":"18","author":"D Wang","year":"2014","unstructured":"Wang D, Gao G. State-of-the-art human gene therapy: part I. Gene Deliv Technol Discov Med. 2014;18:67\u201377.","journal-title":"Gene Deliv Technol Discov Med"},{"key":"1541_CR89","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1134\/S0006297916070063","volume":"81","author":"AN Lukashev","year":"2016","unstructured":"Lukashev AN, Zamyatnin AA. Viral vectors for gene therapy: current state and clinical perspectives. Biochemistry (Mosc). 2016;81:700\u20138.","journal-title":"Biochemistry (Mosc)"},{"key":"1541_CR90","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","volume":"12","author":"C Zhang","year":"2016","unstructured":"Zhang C, Zhou D. Adenoviral vector-based strategies against infectious disease and cancer. Hum Vaccin Immunother. 2016;12:2064\u201374.","journal-title":"Hum Vaccin Immunother"},{"key":"1541_CR91","unstructured":"Mendon\u00e7a SA, Lorincz R, Boucher P, Curiel DT: Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic."},{"key":"1541_CR92","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1073\/pnas.95.5.2509","volume":"95","author":"TC He","year":"1998","unstructured":"He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998;95:2509\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1541_CR93","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/B978-0-12-800276-6.00010-3","volume-title":"Adenoviral vectors for gene therapy (Second Edition)","author":"SP Raikwar","year":"2016","unstructured":"Raikwar SP, Kao CH, Gardner TA. 10\u2013Targeted Adenoviral Vectors III: Transcriptional Targeting. In: Curiel DT, editor. Adenoviral vectors for gene therapy (Second Edition). San Diego: Academic Press; 2016. p. 259\u201392."},{"issue":"8","key":"1541_CR94","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.3390\/cancers13081863","volume":"13","author":"NG Tessarollo","year":"2021","unstructured":"Tessarollo NG, Domingues AC, Antunes F, Luz JC, Rodrigues OA, Cerqueira OL, Strauss BE. Nonreplicating adenoviral vectors: improving tropism and delivery of cancer gene therapy. Cancers. 2021;13(8):1863.","journal-title":"Cancers."},{"key":"1541_CR95","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/1568009617666170222123925","volume":"18","author":"M Sato-Dahlman","year":"2018","unstructured":"Sato-Dahlman M, Yamamoto M. The development of oncolytic adenovirus therapy in the past and future\u2013for the case of pancreatic cancer. Curr Cancer Drug Targets. 2018;18:153\u201361.","journal-title":"Curr Cancer Drug Targets"},{"key":"1541_CR96","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41417-018-0038-x","volume":"26","author":"L Kuryk","year":"2019","unstructured":"Kuryk L, Moller AW, Jaderberg M. Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401. Cancer Gene Ther. 2019;26:26\u201331.","journal-title":"Cancer Gene Ther"},{"key":"1541_CR97","doi-asserted-by":"crossref","first-page":"1259314","DOI":"10.3389\/fonc.2023.1259314","volume":"13","author":"M Garofalo","year":"2023","unstructured":"Garofalo M, Wieczorek M, Anders I, Staniszewska M, Lazniewski M, Prygiel M, Zasada AA, Szczepinska T, Plewczynski D, Salmaso S, et al. Novel combinatorial therapy of oncolytic adenovirus AdV5\/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model. Front Oncol. 2023;13:1259314.","journal-title":"Front Oncol"},{"key":"1541_CR98","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/jmv.25677","volume":"92","author":"L Kuryk","year":"2020","unstructured":"Kuryk L, Moller AW. Chimeric oncolytic Ad5\/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor. J Med Virol. 2020;92:1309\u201315.","journal-title":"J Med Virol"},{"key":"1541_CR99","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.omto.2023.01.002","volume":"28","author":"L Kuryk","year":"2023","unstructured":"Kuryk L, M\u00f8ller ASW. Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models. Mol Ther Oncol. 2023;28:158\u201370.","journal-title":"Mol Ther Oncol"},{"key":"1541_CR100","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.7150\/jca.71992","volume":"13","author":"M Garofalo","year":"2022","unstructured":"Garofalo M, Pancer KW, Wieczorek M, Staniszewska M, Salmaso S, Caliceti P, Kuryk L. From immunosuppression to immunomodulation\u2013turning cold tumours into hot. J Cancer. 2022;13:2884\u201392.","journal-title":"J Cancer"},{"issue":"4","key":"1541_CR101","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3390\/pharmaceutics13040547","volume":"13","author":"M Garofalo","year":"2021","unstructured":"Garofalo M, Bertinato L, Staniszewska M, Wieczorek M, Salmaso S, Schrom S, Rinner B, Pancer KW, Kuryk L. Combination therapy of novel oncolytic adenovirus with anti-PD1 resulted in enhanced anti-cancer effect in syngeneic immunocompetent melanoma mouse model. Pharmaceutics. 2021;13(4):547. https:\/\/doi.org\/10.3390\/pharmaceutics13040547.","journal-title":"Pharmaceutics"},{"key":"1541_CR102","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41587-023-01682-2","volume":"41","author":"CCD Joe","year":"2023","unstructured":"Joe CCD, Chopra N, Nestola P, Niemann J, Douglas AD. Rapid-response manufacturing of adenovirus-vectored vaccines. Nat Biotechnol. 2023;41:314\u20136.","journal-title":"Nat Biotechnol"},{"key":"1541_CR103","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3390\/pr9081430","volume":"9","author":"RG Ferreira","year":"2021","unstructured":"Ferreira RG, Gordon NF, Stock R, Petrides D. Adenoviral vector COVID-19 vaccines: process and cost analysis. Processes. 2021;9:1430.","journal-title":"Processes"},{"key":"1541_CR104","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","volume":"10","author":"N Tatsis","year":"2004","unstructured":"Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther. 2004;10:616\u201329.","journal-title":"Mol Ther"},{"issue":"8","key":"1541_CR105","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/v13081493","volume":"13","author":"M Alhashimi","year":"2021","unstructured":"Alhashimi M, Elkashif A, Sayedahmed EE, Mittal SK. Nonhuman adenoviral vector-based platforms and their utility in designing next generation of vaccines for infectious diseases. Viruses. 2021;13(8):1493.","journal-title":"Viruses"},{"issue":"4","key":"1541_CR106","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/ijms18040686","volume":"18","author":"C Fougeroux","year":"2017","unstructured":"Fougeroux C, Holst P. Future prospects for the development of cost-effective adenovirus vaccines. Int J Mol Sci. 2017;18(4):686. https:\/\/doi.org\/10.3390\/ijms18040686.","journal-title":"Int J Mol Sci"},{"key":"1541_CR107","doi-asserted-by":"crossref","first-page":"e1490856","DOI":"10.1080\/2162402X.2018.1490856","volume":"7","author":"S Zafar","year":"2018","unstructured":"Zafar S, Sorsa S, Siurala M, Hemminki O, Havunen R, Cervera-Carrascon V, Santos JM, Wang H, Lieber A, De Gruijl T, et al. CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. Oncoimmunology. 2018;7:e1490856.","journal-title":"Oncoimmunology"},{"key":"1541_CR108","doi-asserted-by":"crossref","first-page":"916839","DOI":"10.3389\/fonc.2022.916839","volume":"12","author":"L Kuryk","year":"2022","unstructured":"Kuryk L, Rodella G, Staniszewska M, Pancer KW, Wieczorek M, Salmaso S, Caliceti P, Garofalo M. Novel insights into mesothelioma therapy: emerging avenues and future prospects. Front Oncol. 2022;12:916839.","journal-title":"Front Oncol"},{"key":"1541_CR109","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/jmv.25229","volume":"90","author":"L Kuryk","year":"2018","unstructured":"Kuryk L, Moller AW, Garofalo M, Cerullo V, Pesonen S, Alemany R, Jaderberg M. Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5\/3-D24-GM-CSF) in peritoneal mesothelioma mouse model. J Med Virol. 2018;90:1669\u201373.","journal-title":"J Med Virol"},{"key":"1541_CR110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","volume":"4","author":"T Ranki","year":"2016","unstructured":"Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, Lundin J, Linder N, Turkki R, Ristimaki A, et al. Phase I study with ONCOS-102 for the treatment of solid tumors\u2013an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer. 2016;4:17.","journal-title":"J Immunother Cancer"},{"key":"1541_CR111","doi-asserted-by":"crossref","first-page":"e958937","DOI":"10.4161\/21624011.2014.958937","volume":"3","author":"T Ranki","year":"2014","unstructured":"Ranki T, Joensuu T, J\u00e4ger E, Karbach J, Wahle C, Kairemo K, Alanko T, Partanen K, Turkki R, Linder N, et al. Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8. Oncoimmunology. 2014;3:e958937.","journal-title":"Oncoimmunology"},{"issue":"17","key":"1541_CR112","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1158\/1078-0432.CCR-23-3874","volume":"30","author":"SA Pakola","year":"2024","unstructured":"Pakola SA, Peltola KJ, Clubb JHA, Jirovec E, Haybout L, Kudling TV, Alanko T, Korpisaari R, Juteau S, Jaakkola M, et al. Safety, efficacy, and biological data of T cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial. Clin Cancer Res. 2024;30(17):3715\u201325.","journal-title":"Clin Cancer Res"},{"key":"1541_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114300","author":"L Kuryk","year":"2024","unstructured":"Kuryk L, Mathlouthi S, Wieczorek M, Gad B, Rinner B, Malfanti A, Mastrotto F, Salmaso S, Caliceti P, Garofalo M. Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model. Eur J Pharm Biopharm. 2024. https:\/\/doi.org\/10.1016\/j.ejpb.2024.114300.","journal-title":"Eur J Pharm Biopharm"},{"key":"1541_CR114","doi-asserted-by":"crossref","first-page":"e1105429","DOI":"10.1080\/2162402X.2015.1105429","volume":"5","author":"C Capasso","year":"2016","unstructured":"Capasso C, Hirvinen M, Garofalo M, Romaniuk D, Kuryk L, Sarvela T, Vitale A, Antopolsky M, Magarkar A, Viitala T, et al. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncoimmunology. 2016;5:e1105429.","journal-title":"Oncoimmunology"},{"key":"1541_CR115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.omto.2021.02.006","volume":"20","author":"E Ylosmaki","year":"2021","unstructured":"Ylosmaki E, Ylosmaki L, Fusciello M, Martins B, Ahokas P, Cojoc H, Uoti A, Feola S, Kreutzman A, Ranki T, et al. Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform. Mol Ther Oncol. 2021;20:459\u201369.","journal-title":"Mol Ther Oncol"},{"key":"1541_CR116","doi-asserted-by":"crossref","first-page":"826164","DOI":"10.3389\/fimmu.2022.826164","volume":"13","author":"S Feola","year":"2022","unstructured":"Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Fluhler V, De Giorgi C, Fusciello M, Pesonen S, Yl\u00f6sm\u00e4ki E, et al. Peptides-coated oncolytic vaccines for cancer personalized medicine. Front Immunol. 2022;13:826164.","journal-title":"Front Immunol"},{"key":"1541_CR117","doi-asserted-by":"crossref","first-page":"e71156","DOI":"10.7554\/eLife.71156","volume":"11","author":"S Feola","year":"2022","unstructured":"Feola S, Chiaro J, Martins B, Russo S, Fusciello M, Ylosmaki E, Bonini C, Ruggiero E, Hamdan F, Feodoroff M, et al. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines. Elife. 2022;11:e71156.","journal-title":"Elife"},{"key":"1541_CR118","doi-asserted-by":"crossref","first-page":"7056","DOI":"10.1038\/s41467-023-42668-7","volume":"14","author":"J Chiaro","year":"2023","unstructured":"Chiaro J, Antignani G, Feola S, Feodoroff M, Martins B, Cojoc H, Russo S, Fusciello M, Hamdan F, Ferrari V, et al. Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors. Nat Commun. 2023;14:7056.","journal-title":"Nat Commun"},{"issue":"3","key":"1541_CR119","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/ijms20030621","volume":"20","author":"L Kuryk","year":"2019","unstructured":"Kuryk L, Moller AW, Vuolanto A, Pesonen S, Garofalo M, Cerullo V, Jaderberg M. Optimization of early steps in oncolytic adenovirus ONCOS-401 production in T-175 and HYPERFlasks. Int J Mol Sci. 2019;20(3):621.","journal-title":"Int J Mol Sci"},{"key":"1541_CR120","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1073\/pnas.55.6.1467","volume":"55","author":"MD Hoggan","year":"1966","unstructured":"Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A. 1966;55:1467\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1541_CR121","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","volume":"75","author":"H Nakai","year":"2001","unstructured":"Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol. 2001;75:6969\u201376.","journal-title":"J Virol"},{"key":"1541_CR122","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","volume":"1","author":"RJ Samulski","year":"2014","unstructured":"Samulski RJ, Muzyczka N. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol. 2014;1:427\u201351.","journal-title":"Annu Rev Virol"},{"key":"1541_CR123","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00253-017-8670-1","volume":"102","author":"JJ Aponte-Ubillus","year":"2018","unstructured":"Aponte-Ubillus JJ, Barajas D, Peltier J, Bardliving C, Shamlou P, Gold D. Molecular design for recombinant adeno-associated virus (rAAV) vector production. Appl Microbiol Biotechnol. 2018;102:1045\u201354.","journal-title":"Appl Microbiol Biotechnol"},{"key":"1541_CR124","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","volume":"7","author":"JY Dong","year":"1996","unstructured":"Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther. 1996;7:2101\u201312.","journal-title":"Hum Gene Ther"},{"key":"1541_CR125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/rr6","volume":"1","author":"TR Flotte","year":"2000","unstructured":"Flotte TR. Size does matter: overcoming the adeno-associated virus packaging limit. Respir Res. 2000;1:16\u20138.","journal-title":"Respir Res"},{"key":"1541_CR126","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","volume":"79","author":"JC Grieger","year":"2005","unstructured":"Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol. 2005;79:9933\u201344.","journal-title":"J Virol"},{"key":"1541_CR127","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.omtm.2023.01.006","volume":"28","author":"K Krotova","year":"2023","unstructured":"Krotova K, Kuoch Yoshitomi H, Caine C, Aslanidi G. Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model. Mol Ther Methods Clin Dev. 2023;28:301\u201311.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1541_CR128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2018.12.004","volume":"12","author":"JA Hensel","year":"2019","unstructured":"Hensel JA, Khattar V, Ashton R, Ponnazhagan S. Recombinant AAV-CEA tumor vaccine in combination with an immune adjuvant breaks tolerance and provides protective immunity. Mol Ther Oncol. 2019;12:41\u20138.","journal-title":"Mol Ther Oncol"},{"key":"1541_CR129","first-page":"1","volume":"36","author":"L Vannucci","year":"2013","unstructured":"Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M. Viral vectors: a look back and ahead on gene transfer technology. New Microbiol. 2013;36:1\u201322.","journal-title":"New Microbiol"},{"key":"1541_CR130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.0959-9673.2004.00383.x","volume":"85","author":"R Lachmann","year":"2004","unstructured":"Lachmann R. Herpes simplex virus-based vectors. Int J Exp Pathol. 2004;85:177\u201390.","journal-title":"Int J Exp Pathol"},{"key":"1541_CR131","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/gt.2009.42","volume":"16","author":"AL Epstein","year":"2009","unstructured":"Epstein AL. Progress and prospects: biological properties and technological advances of herpes simplex virus type 1-based amplicon vectors. Gene Ther. 2009;16:709\u201315.","journal-title":"Gene Ther"},{"key":"1541_CR132","first-page":"123","volume":"4","author":"R Manservigi","year":"2010","unstructured":"Manservigi R, Argnani R, Marconi P. HSV recombinant vectors for gene therapy. Open Virol J. 2010;4:123\u201356.","journal-title":"Open Virol J"},{"key":"1541_CR133","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ymthe.2005.07.357","volume":"12","author":"KJ Pulkkanen","year":"2005","unstructured":"Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther. 2005;12:585\u201398.","journal-title":"Mol Ther"},{"key":"1541_CR134","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2174\/138920112800958751","volume":"13","author":"J Wong","year":"2012","unstructured":"Wong J, Lee C, Zhang K, Rennie PS, Jia W. Targeted oncolytic herpes simplex viruses for aggressive cancers. Curr Pharm Biotechnol. 2012;13:1786\u201394.","journal-title":"Curr Pharm Biotechnol"},{"key":"1541_CR135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","volume":"4","author":"CS Lee","year":"2017","unstructured":"Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, Zhao C, Zheng Z, Shu Y, Wu X, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 2017;4:43\u201363.","journal-title":"Genes Dis"},{"issue":"4","key":"1541_CR136","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mog2.55","volume":"2","author":"L Xie","year":"2023","unstructured":"Xie L, Han Y, Liu Y, Zhou Y, Yu J, von Brunn A, Lei J. Viral vector-based cancer treatment and current clinical applications. MedComm Oncol. 2023;2(4):55.","journal-title":"MedComm Oncol"},{"key":"1541_CR137","doi-asserted-by":"crossref","first-page":"1199068","DOI":"10.3389\/fmolb.2023.1199068","volume":"10","author":"R Nabi","year":"2023","unstructured":"Nabi R, Musarrat F. Menk P Lima JC, Langohr IM, Chouljenko VN, Kousoulas KG: The Oncolytic herpes simplex virus type-1 (HSV-1) vaccine strain VC2 causes intratumor infiltration of functionally active T cells and inhibition of tumor metastasis and pro-tumor genes VEGF and PDL1 expression in the 4T1\/Balb\/c mouse model of stage four breast cancer. Front Mol Biosci. 2023;10:1199068.","journal-title":"Front Mol Biosci"},{"key":"1541_CR138","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","volume":"12","author":"JC Hu","year":"2006","unstructured":"Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12:6737\u201347.","journal-title":"Clin Cancer Res"},{"key":"1541_CR139","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-10-0196","volume":"16","author":"KJ Harrington","year":"2010","unstructured":"Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, Renouf LC, Thway K, Sibtain A, McNeish IA, et al. Phase I\/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III\/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010;16:4005\u201315.","journal-title":"Clin Cancer Res"},{"key":"1541_CR140","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","volume":"27","author":"NN Senzer","year":"2009","unstructured":"Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27:5763\u201371.","journal-title":"J Clin Oncol"},{"key":"1541_CR141","doi-asserted-by":"crossref","first-page":"e1115641","DOI":"10.1080\/2162402X.2015.1115641","volume":"5","author":"J Pol","year":"2016","unstructured":"Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5:e1115641.","journal-title":"Oncoimmunology"},{"key":"1541_CR142","doi-asserted-by":"crossref","first-page":"9553","DOI":"10.1200\/JCO.2022.40.16_suppl.9553","volume":"40","author":"MM Milhem","year":"2022","unstructured":"Milhem MM, Vanderwalde AM, Bowles TL, Sacco JJ, Niu J, Tsai KK, Chesney JA, Chmielowski B, Samson A, Rhodes TD, et al. Updated results from the skin cancer cohorts from an ongoing phase 1\/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE). J Clin Oncol. 2022;40:9553\u20139553.","journal-title":"J Clin Oncol"},{"key":"1541_CR143","doi-asserted-by":"crossref","first-page":"e002224","DOI":"10.1136\/jitc-2020-002224","volume":"9","author":"Z Bo","year":"2021","unstructured":"Bo Z, Jing H, Jialin T, Sheng H, Suxia L, Zhiguo L, Fuxiang Z, Shiyun T, Jieer Y, Qing C, et al. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I\/II clinical trial. J Immunother Cancer. 2021;9:e002224.","journal-title":"J Immunother Cancer"},{"key":"1541_CR144","unstructured":"Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID, World Health O: Smallpox and its eradication \/ F. Fenner ... [et al.]. Geneva: World Health Organization; 1988."},{"key":"1541_CR145","first-page":"425","volume":"367","author":"ZS Moore","year":"2006","unstructured":"Moore ZS, Seward JF, Lane JM. The Lancet. Smallpox. 2006;367:425\u201335.","journal-title":"Smallpox"},{"key":"1541_CR146","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1586\/erv.11.79","volume":"10","author":"SR Walsh","year":"2011","unstructured":"Walsh SR, Dolin R. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines. 2011;10:1221\u201340.","journal-title":"Expert Rev Vaccines"},{"key":"1541_CR147","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","volume":"7","author":"ZS Guo","year":"2019","unstructured":"Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019;7:6.","journal-title":"J Immunother Cancer"},{"key":"1541_CR148","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0378-1119(83)90163-4","volume":"25","author":"GL Smith","year":"1983","unstructured":"Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene. 1983;25:21\u20138.","journal-title":"Gene"},{"key":"1541_CR149","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1080\/21645515.2020.1840887","volume":"17","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Dong L, Zhao C, Zheng P, Zhang X, Xu J. Vaccinia virus-based vector against infectious diseases and tumors. Hum Vaccin Immunother. 2021;17:1578\u201385.","journal-title":"Hum Vaccin Immunother"},{"key":"1541_CR150","first-page":"31","volume":"269","author":"CM Byrd","year":"2004","unstructured":"Byrd CM, Hruby DE. Construction of recombinant vaccinia virus: cloning into the thymidine kinase locus. Methods Mol Biol. 2004;269:31\u201340.","journal-title":"Methods Mol Biol"},{"key":"1541_CR151","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ijc.29068","volume":"136","author":"S Parviainen","year":"2015","unstructured":"Parviainen S, Ahonen M, Diaconu I, Kipar A, Siurala M, Vaha-Koskela M, Kanerva A, Cerullo V, Hemminki A. GMCSF-armed vaccinia virus induces an antitumor immune response. Int J Cancer. 2015;136:1065\u201372.","journal-title":"Int J Cancer"},{"key":"1541_CR152","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","volume":"19","author":"J Heo","year":"2013","unstructured":"Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329\u201336.","journal-title":"Nat Med"},{"key":"1541_CR153","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-3232","volume":"23","author":"LK Mell","year":"2017","unstructured":"Mell LK, Brumund KT, Daniels GA, Advani SJ, Zakeri K, Wright ME, Onyeama SJ, Weisman RA, Sanghvi PR, Martin PJ, Szalay AA. Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma. Clin Cancer Res. 2017;23:5696\u2013702.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1541_CR154","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/pharmaceutics15030846","volume":"15","author":"K Nemirov","year":"2023","unstructured":"Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L. Lentiviral vectors as a vaccine platform against infectious diseases. Pharmaceutics. 2023;15(3):846.","journal-title":"Pharmaceutics"},{"key":"1541_CR155","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/JOM.0000000000000879","volume":"58","author":"R Schlimgen","year":"2016","unstructured":"Schlimgen R, Howard J, Wooley D, Thompson M, Baden LR, Yang OO, Christiani DC, Mostoslavsky G, Diamond DV, Duane EG, et al. Risks associated with lentiviral vector exposures and prevention strategies. J Occup Environ Med. 2016;58:1159\u201366.","journal-title":"J Occup Environ Med"},{"key":"1541_CR156","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-4614-4433-6_9","volume":"762","author":"M Rossetti","year":"2013","unstructured":"Rossetti M, Cavarelli M, Gregori S, Scarlatti G. HIV-derived vectors for gene therapy targeting dendritic cells. Adv Exp Med Biol. 2013;762:239\u201361.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"1541_CR157","first-page":"1528","volume":"13","author":"RP Labb\u00e9","year":"2021","unstructured":"Labb\u00e9 RP, Vessillier S, Rafiq QA. Lentiviral vectors for T cell engineering: clinical applications. Bioprocess Future Perspect Viruses. 2021;13(8):1528.","journal-title":"Bioprocess Future Perspect. Viruses"},{"key":"1541_CR158","first-page":"69","volume":"3","author":"D Clements","year":"2014","unstructured":"Clements D, Helson E, Gujar SA, Lee PW. Reovirus in cancer therapy: an evidence-based review. Oncolytic Virother. 2014;3:69\u201382.","journal-title":"Oncolytic Virother"},{"key":"1541_CR159","first-page":"457","volume":"53","author":"K Figova","year":"2006","unstructured":"Figova K, Hrabeta J, Eckschlager T. Reovirus\u2013possible therapy of cancer. Neoplasma. 2006;53:457\u201362.","journal-title":"Neoplasma"},{"key":"1541_CR160","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1038\/cddis.2013.259","volume":"4","author":"JS Carew","year":"2013","unstructured":"Carew JS, Espitia CM, Zhao W, Kelly KR, Coffey M, Freeman JW, Nawrocki ST. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. Cell Death Dis. 2013;4:e728.","journal-title":"Cell Death Dis"},{"key":"1541_CR161","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00280-017-3260-6","volume":"79","author":"D Mahalingam","year":"2017","unstructured":"Mahalingam D, Fountzilas C, Moseley J, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Coffey M, Thompson B, Sarantopoulos J. A phase II study of REOLYSIN. Cancer Chemother Pharmacol. 2017;79:697\u2013703.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"1541_CR162","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.3390\/cancers12113219","volume":"12","author":"L M\u00fcller","year":"2020","unstructured":"M\u00fcller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Past, present and future of oncolytic reovirus. Cancers. 2020;12(11):3219.","journal-title":"Cancers"},{"key":"1541_CR163","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective. Nat Rev Urol. 2014;11:153\u201362.","journal-title":"Nat Rev Urol"},{"issue":"11","key":"1541_CR164","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3390\/vaccines11111633","volume":"11","author":"A Hargrave","year":"2023","unstructured":"Hargrave A, Mustafa AS, Hanif A, Tunio JH, Hanif SNM. Recent advances in cancer immunotherapy with a focus on FDA-approved vaccines and neoantigen-based vaccines. Vaccines. 2023;11(11):1633.","journal-title":"Vaccines"},{"key":"1541_CR165","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41585-020-0346-4","volume":"17","author":"JH van Puffelen","year":"2020","unstructured":"van Puffelen JH, Keating ST, Oosterwijk E, van der Heijden AG, Netea MG, Joosten LAB, Vermeulen SH. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat Rev Urol. 2020;17:513\u201325.","journal-title":"Nat Rev Urol"},{"key":"1541_CR166","doi-asserted-by":"crossref","first-page":"110393","DOI":"10.1016\/j.biopha.2020.110393","volume":"129","author":"J Han","year":"2020","unstructured":"Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother. 2020;129:110393.","journal-title":"Biomed Pharmacother"},{"key":"1541_CR167","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"M Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Turkeri L, Marreaud S, Collette S, Oosterlinck W. Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65:69\u201376.","journal-title":"Eur Urol"},{"key":"1541_CR168","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.jctube.2020.100149","volume":"19","author":"R Waked","year":"2020","unstructured":"Waked R, Choucair J, Chehata N, Haddad E, Saliba G. Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) treatment\u2019s severe complications: a single institution review of incidence, presentation and treatment outcome. J Clin Tuberc Other Mycobact Dis. 2020;19:100149.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"1541_CR169","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/curroncol31020079","volume":"31","author":"S Lidagoster","year":"2024","unstructured":"Lidagoster S, Ben-David R, De Leon B, Sfakianos JP. BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer. Curr Oncol. 2024;31:1063\u201378.","journal-title":"Curr Oncol"},{"key":"1541_CR170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S202006","volume":"9","author":"S Guallar-Garrido","year":"2020","unstructured":"Guallar-Garrido S, Juli\u00e1n E. Bacillus calmette-gu\u00e9rin (BCG) therapy for bladder cancer: an update. Immunotargets Ther. 2020;9:1\u201311.","journal-title":"Immunotargets Ther"},{"issue":"7","key":"1541_CR171","first-page":"1937","volume":"15","author":"F Del Giudice","year":"2023","unstructured":"Del Giudice F, Asero V, Bologna E, Scornajenghi CM, Carino D, Dolci V, Viscuso P, Salciccia S, Sciarra A, D\u2019Andrea D, et al. Efficacy of different bacillus of calmette-gu\u00e9rin (BCG) strains on recurrence rates among intermediate\/high-risk non-muscle invasive bladder cancers (NMIBCs): single-arm study systematic review. Cumul Netw Meta-Anal Cancers. 2023;15(7):1937.","journal-title":"Cumul Netw Meta-Anal Cancers"},{"key":"1541_CR172","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.vaccine.2017.12.010","volume":"36","author":"T Cernuschi","year":"2018","unstructured":"Cernuschi T, Malvolti S, Nickels E, Friede M. Bacillus Calmette-Gu\u00e9rin (BCG) vaccine: a global assessment of demand and supply balance. Vaccine. 2018;36:498\u2013506.","journal-title":"Vaccine"},{"key":"1541_CR173","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bju.14915","volume":"125","author":"J Taylor","year":"2020","unstructured":"Taylor J, Becher E, Steinberg GD. Update on the guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2020;125:197\u2013205.","journal-title":"BJU Int"},{"key":"1541_CR174","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/PPO.0b013e3181eb33d7","volume":"16","author":"DT Le","year":"2010","unstructured":"Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J. 2010;16:304\u201310.","journal-title":"Cancer J"},{"key":"1541_CR175","doi-asserted-by":"crossref","first-page":"730824","DOI":"10.3389\/fonc.2021.730824","volume":"11","author":"IY Filin","year":"2021","unstructured":"Filin IY, Kitaeva KV, Rutland CS, Rizvanov AA, Solovyeva VV. Recent Advances in experimental dendritic cell vaccines for cancer. Front Oncol. 2021;11:730824.","journal-title":"Front Oncol"},{"key":"1541_CR176","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27:74\u201395.","journal-title":"Cell Res"},{"key":"1541_CR177","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s40425-019-0716-8","volume":"7","author":"J Calmeiro","year":"2019","unstructured":"Calmeiro J, Carrascal M, Gomes C, Falc\u00e3o A, Cruz MT, Neves BM. Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy. J Immunother Cancer. 2019;7:238.","journal-title":"J Immunother Cancer"},{"key":"1541_CR178","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/imt.09.43","volume":"2","author":"RL Sabado","year":"2010","unstructured":"Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy. 2010;2:37\u201356.","journal-title":"Immunotherapy"},{"key":"1541_CR179","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1084\/jem.179.4.1109","volume":"179","author":"F Sallusto","year":"1994","unstructured":"Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte\/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109\u201318.","journal-title":"J Exp Med"},{"key":"1541_CR180","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12967-015-0528-7","volume":"13","author":"C Massa","year":"2015","unstructured":"Massa C, Thomas C, Wang E, Marincola F, Seliger B. Different maturation cocktails provide dendritic cells with different chemoattractive properties. J Transl Med. 2015;13:175.","journal-title":"J Transl Med"},{"key":"1541_CR181","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","volume":"24","author":"S Wilgenhof","year":"2013","unstructured":"Wilgenhof S, Van Nuffel AMT, Benteyn D, Corthals J, Aerts C, Heirman C, Van Riet I, Bonehill A, Thielemans K, Neyns B. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol. 2013;24:2686\u201393.","journal-title":"Ann Oncol"},{"key":"1541_CR182","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.trsl.2015.07.008","volume":"168","author":"J Constantino","year":"2016","unstructured":"Constantino J, Gomes C, Falc\u00e3o A, Cruz MT, Neves BM. Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. Transl Res. 2016;168:74\u201395.","journal-title":"Transl Res"},{"key":"1541_CR183","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","volume":"115","author":"CS Higano","year":"2009","unstructured":"Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670\u20139.","journal-title":"Cancer"},{"key":"1541_CR184","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17:3520\u20136.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1541_CR185","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3390\/cells12172147","volume":"12","author":"K-W Lee","year":"2023","unstructured":"Lee K-W, Yam JW, Mao X. Dendritic cell vaccines: a shift from conventional approach to new generations. In Cells. 2023;12(17):2147.","journal-title":"In Cells"},{"key":"1541_CR186","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.4049\/jimmunol.1401243","volume":"193","author":"S Balan","year":"2014","unstructured":"Balan S, Ollion V, Colletti N, Chelbi R, Montanana-Sanchis F, Liu H, Vu Manh TP, Sanchez C, Savoret J, Perrot I, et al. Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells. J Immunol. 2014;193:1622\u201335.","journal-title":"J Immunol"},{"key":"1541_CR187","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3389\/fimmu.2019.01014","volume":"10","author":"R Noubade","year":"2019","unstructured":"Noubade R, Majri-Morrison S, Tarbell KV. Beyond cDC1: emerging roles of DC crosstalk in cancer immunity. Front Immunol. 2019;10:1014.","journal-title":"Front Immunol"},{"key":"1541_CR188","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1084\/jem.20030448","volume":"198","author":"A MartIn-Fontecha","year":"2003","unstructured":"MartIn-Fontecha A, Sebastiani S, H\u00f6pken UE, Uguccioni M, Lipp M, Lanzavecchia A, Sallusto F. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med. 2003;198:615\u201321.","journal-title":"J Exp Med"},{"key":"1541_CR189","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.coi.2005.01.004","volume":"17","author":"GJ Adema","year":"2005","unstructured":"Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol. 2005;17:170\u20134.","journal-title":"Curr Opin Immunol"},{"key":"1541_CR190","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/vaccines3020344","volume":"3","author":"CL Chiang","year":"2015","unstructured":"Chiang CL, Coukos G, Kandalaft LE. Whole tumor antigen vaccines: where are we? Vaccines (Basel). 2015;3:344\u201372.","journal-title":"Vaccines (Basel)"},{"key":"1541_CR191","first-page":"491","volume":"22","author":"X Zhang","year":"2023","unstructured":"Zhang X, Cui H, Zhang W, Li Z, Gao J. Engineered tumor cell-derived vaccines against cancer: the art of combating poison with poison. Bioact Mater. 2023;22:491\u2013517.","journal-title":"Bioact Mater"},{"key":"1541_CR192","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/35011084","volume":"405","author":"VA Fadok","year":"2000","unstructured":"Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature. 2000;405:85\u201390.","journal-title":"Nature"},{"key":"1541_CR193","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1471-4906(01)01860-9","volume":"22","author":"M Larsson","year":"2001","unstructured":"Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol. 2001;22:141\u20138.","journal-title":"Trends Immunol"},{"key":"1541_CR194","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1182\/blood.V96.13.4300","volume":"96","author":"P Rovere","year":"2000","unstructured":"Rovere P, Peri G, Fazzini F, Bottazzi B, Doni A, Bondanza A, Zimmermann VS, Garlanda C, Fascio U, Sabbadini MG, et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood. 2000;96:4300\u20136.","journal-title":"Blood"},{"key":"1541_CR195","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(02)09552-1","volume":"360","author":"F Andre","year":"2002","unstructured":"Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002;360:295\u2013305.","journal-title":"Lancet"},{"key":"1541_CR196","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1189\/jlb.0206094","volume":"80","author":"N Chaput","year":"2006","unstructured":"Chaput N, Flament C, Viaud S, Taieb J, Roux S, Spatz A, Andr\u00e9 F, LePecq JB, Boussac M, Garin J, et al. Dendritic cell derived-exosomes: biology and clinical implementations. J Leukoc Biol. 2006;80:471\u20138.","journal-title":"J Leukoc Biol"},{"key":"1541_CR197","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1158\/0008-5472.CAN-04-3804","volume":"65","author":"R Gastpar","year":"2005","unstructured":"Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, Multhoff G. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 2005;65:5238\u201347.","journal-title":"Cancer Res"},{"key":"1541_CR198","first-page":"2127","volume":"63","author":"Z Su","year":"2003","unstructured":"Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003;63:2127\u201333.","journal-title":"Cancer Res"},{"key":"1541_CR199","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1158\/1078-0432.CCR-06-2937","volume":"13","author":"EJ Small","year":"2007","unstructured":"Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, et al. Granulocyte macrophage colony-stimulating factor\u2013secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:3883\u201391.","journal-title":"Clin Cancer Res"},{"key":"1541_CR200","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1200\/JCO.2003.03.091","volume":"21","author":"R Salgia","year":"2003","unstructured":"Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003;21:624\u201330.","journal-title":"J Clin Oncol"},{"key":"1541_CR201","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1200\/JCO.2002.08.071","volume":"20","author":"VK Sondak","year":"2002","unstructured":"Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest oncology group. J Clin Oncol. 2002;20:2058\u201366.","journal-title":"J Clin Oncol"},{"key":"1541_CR202","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1200\/JCO.2002.08.072","volume":"20","author":"Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK, Group SO","year":"2002","unstructured":"Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK, Group SO. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol. 2002;20:2067\u201375.","journal-title":"J Clin Oncol"},{"key":"1541_CR203","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.suc.2014.07.005","volume":"94","author":"J Ozao-Choy","year":"2014","unstructured":"Ozao-Choy J, Lee DJ, Faries MB. Melanoma vaccines: mixed past, promising future. Surg Clin North Am. 2014;94:1017\u201330.","journal-title":"Surg Clin North Am"},{"key":"1541_CR204","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/14760584.2018.1434000","volume":"17","author":"WS Bowen","year":"2018","unstructured":"Bowen WS, Svrivastava AK, Batra L, Barsoumian H, Shirwan H. Current challenges for cancer vaccine adjuvant development. Expert Rev Vaccines. 2018;17:207\u201315.","journal-title":"Expert Rev Vaccines"},{"key":"1541_CR205","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.4049\/jimmunol.0802982","volume":"182","author":"AG Sikora","year":"2009","unstructured":"Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, et al. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol. 2009;182:7398\u2013407.","journal-title":"J Immunol"},{"key":"1541_CR206","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/(SICI)1097-0215(19980610)76:6<817::AID-IJC9>3.0.CO;2-0","volume":"76","author":"M Reddish","year":"1998","unstructured":"Reddish M, MacLean GD, Koganty RR, Kan-Mitchell J, Jones V, Mitchell MS, Longenecker BM. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer. 1998;76:817\u201323.","journal-title":"Int J Cancer"},{"key":"1541_CR207","doi-asserted-by":"crossref","first-page":"627932","DOI":"10.3389\/fimmu.2021.627932","volume":"12","author":"SJ Paston","year":"2021","unstructured":"Paston SJ, Brentville VA, Symonds P, Durrant LG. Cancer vaccines, adjuvants, and delivery systems. Front Immunol. 2021;12:627932.","journal-title":"Front Immunol"},{"key":"1541_CR208","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/ni1059","volume":"5","author":"Y Yang","year":"2004","unstructured":"Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol. 2004;5:508\u201315.","journal-title":"Nat Immunol"},{"key":"1541_CR209","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1158\/2326-6066.CIR-13-0223","volume":"2","author":"GG Zom","year":"2014","unstructured":"Zom GG, Khan S, Britten CM, Sommandas V, Camps MG, Loof NM, Budden CF, Meeuwenoord NJ, Filippov DV, van der Marel GA, et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. Cancer Immunol Res. 2014;2:756\u201364.","journal-title":"Cancer Immunol Res"},{"key":"1541_CR210","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1158\/2326-6066.CIR-17-0607","volume":"6","author":"KD Moynihan","year":"2018","unstructured":"Moynihan KD, Holden RL, Mehta NK, Wang C, Karver MR, Dinter J, Liang S, Abraham W, Melo MB, Zhang AQ, et al. Enhancement of peptide vaccine immunogenicity by increasing lymphatic drainage and boosting serum stability. Cancer Immunol Res. 2018;6:1025\u201338.","journal-title":"Cancer Immunol Res"},{"key":"1541_CR211","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7883\/yoken.JJID.2002.37","volume":"55","author":"S Yamamoto","year":"2002","unstructured":"Yamamoto S, Yamamoto T, Nojima Y, Umemori K, Phalen S, McMurray DN, Kuramoto E, Iho S, Takauji R, Sato Y, et al. Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development. Jpn J Infect Dis. 2002;55:37\u201344.","journal-title":"Jpn J Infect Dis"},{"key":"1541_CR212","first-page":"165","volume":"104","author":"HL Davis","year":"2000","unstructured":"Davis HL. CpG motifs for optimization of DNA vaccines. Dev Biol (Basel). 2000;104:165\u20139.","journal-title":"Dev Biol (Basel)"},{"key":"1541_CR213","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1080\/13102818.2016.1207488","volume":"30","author":"S Wen","year":"2016","unstructured":"Wen S, Zhang J, Zhou P, Luo C, Liu Y, Xu Z, Chen X, Ma H. The anti-tumour effect of a DNA vaccine carrying a fusion gene of human VEGFR2 and IL-12. Biotechnol Biotechnol Equip. 2016;30:956\u201362.","journal-title":"Biotechnol Biotechnol Equip"},{"key":"1541_CR214","doi-asserted-by":"crossref","first-page":"1123805","DOI":"10.3389\/fimmu.2023.1123805","volume":"14","author":"R Gupta","year":"2023","unstructured":"Gupta R, Arora K, Roy SS, Joseph A, Rastogi R, Arora NM, Kundu PK. Platforms, advances, and technical challenges in virus-like particles-based vaccines. Front Immunol. 2023;14:1123805.","journal-title":"Front Immunol"},{"issue":"9","key":"1541_CR215","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3390\/v14091905","volume":"14","author":"J He","year":"2022","unstructured":"He J, Yu L, Lin X, Liu X, Zhang Y, Yang F, Deng W. Virus-like particles as nanocarriers for intracellular delivery of biomolecules and compounds. Viruses. 2022;14(9):1905.","journal-title":"Viruses"},{"key":"1541_CR216","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41565-022-01129-w","volume":"17","author":"G Guerrini","year":"2022","unstructured":"Guerrini G, Magr\u00ec D, Gioria S, Medaglini D, Calzolai L. Characterization of nanoparticles-based vaccines for COVID-19. Nat Nanotechnol. 2022;17:570\u20136.","journal-title":"Nat Nanotechnol"},{"key":"1541_CR217","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2174\/1381612823666161116114732","volume":"23","author":"A Elhissi","year":"2017","unstructured":"Elhissi A. Liposomes for pulmonary drug delivery: the role of formulation and inhalation device design. Curr Pharm Des. 2017;23:362\u201372.","journal-title":"Curr Pharm Des"},{"key":"1541_CR218","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/mt.2011.81","volume":"19","author":"H Li","year":"2011","unstructured":"Li H, Lasaro MO, Jia B, Lin SW, Haut LH, High KA, Ertl HC. Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates. Mol Ther. 2011;19:2021\u201330.","journal-title":"Mol Ther"},{"key":"1541_CR219","doi-asserted-by":"crossref","first-page":"666666","DOI":"10.3389\/fimmu.2021.666666","volume":"12","author":"HCJ Ertl","year":"2021","unstructured":"Ertl HCJ. T cell-mediated immune responses to AAV and AAV vectors. Front Immunol. 2021;12:666666.","journal-title":"Front Immunol"},{"key":"1541_CR220","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tibs.2021.03.002","volume":"46","author":"M Hasanpourghadi","year":"2021","unstructured":"Hasanpourghadi M, Novikov M, Ertl HCJ. COVID-19 vaccines based on adenovirus vectors. Trends Biochem Sci. 2021;46:429\u201330.","journal-title":"Trends Biochem Sci"},{"key":"1541_CR221","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40265-023-01836-1","volume":"83","author":"HCJ Ertl","year":"2023","unstructured":"Ertl HCJ. Mitigating serious adverse events in gene therapy with aav vectors: vector dose and immunosuppression. Drugs. 2023;83:287\u201398.","journal-title":"Drugs"},{"key":"1541_CR222","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-4-1","volume":"4","author":"RS DiPaola","year":"2006","unstructured":"DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7\u20131, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006;4:1.","journal-title":"J Transl Med"},{"key":"1541_CR223","doi-asserted-by":"crossref","first-page":"612747","DOI":"10.3389\/fimmu.2021.612747","volume":"12","author":"JL Palgen","year":"2021","unstructured":"Palgen JL, Feraoun Y, Dzangue-Tchoupou G, Joly C, Martinon F, Le Grand R, Beignon AS. Optimize prime\/boost vaccine strategies: trained immunity as a new player in the game. Front Immunol. 2021;12:612747.","journal-title":"Front Immunol"},{"key":"1541_CR224","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671\u201381.","journal-title":"Lancet"},{"key":"1541_CR225","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","volume":"9","author":"SJ McConkey","year":"2003","unstructured":"McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med. 2003;9:729\u201335.","journal-title":"Nat Med"},{"issue":"14","key":"1541_CR226","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.3390\/ijms21144821","volume":"21","author":"STF Bots","year":"2020","unstructured":"Bots STF, Hoeben RC. Non-human primate-derived adenoviruses for future use as oncolytic agents? Int J Mol Sci. 2020;21(14):4821.","journal-title":"Int J Mol Sci"},{"key":"1541_CR227","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","volume":"26","author":"JM Ricca","year":"2018","unstructured":"Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, Wolchok JD, Zamarin D. Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol Ther. 2018;26:1008\u201319.","journal-title":"Mol Ther"},{"key":"1541_CR228","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","volume":"5","author":"KM Hege","year":"2017","unstructured":"Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017;5:22.","journal-title":"J Immunother Cancer"},{"key":"1541_CR229","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"Ruella M, Maus MV. Catch me if you can: leukemia escape after cd19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357\u201362.","journal-title":"Comput Struct Biotechnol J"},{"key":"1541_CR230","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1158\/1078-0432.CCR-19-1339","volume":"26","author":"G Heng","year":"2020","unstructured":"Heng G, Jia J, Li S, Fu G, Wang M, Qin D, Li Y, Pei L, Tian X, Zhang J, et al. Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor t cells in relapsed\/refractory acute lymphoblastic leukemia. Clin Cancer Res. 2020;26:1606\u201315.","journal-title":"Clin Cancer Res"},{"key":"1541_CR231","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/med.21818","volume":"42","author":"H Hanssens","year":"2022","unstructured":"Hanssens H, Meeus F, De Veirman K, Breckpot K, Devoogdt N. The antigen-binding moiety in the driver\u2019s seat of CARs. Med Res Rev. 2022;42:306\u201342.","journal-title":"Med Res Rev"},{"key":"1541_CR232","doi-asserted-by":"crossref","first-page":"886546","DOI":"10.3389\/fimmu.2022.886546","volume":"13","author":"AN Khan","year":"2022","unstructured":"Khan AN, Chowdhury A, Karulkar A, Jaiswal AK, Banik A, Asija S, Purwar R. Immunogenicity of CAR-T cell therapeutics: evidence. Mech Mitigation Front Immunol. 2022;13:886546.","journal-title":"Mech Mitigation Front Immunol"},{"key":"1541_CR233","doi-asserted-by":"crossref","first-page":"112692","DOI":"10.1016\/j.jim.2019.112692","volume":"476","author":"B Potthoff","year":"2020","unstructured":"Potthoff B, McBlane F, Spindeldreher S, Sickert D. A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel. J Immunol Methods. 2020;476:112692.","journal-title":"J Immunol Methods"},{"key":"1541_CR234","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","volume":"18","author":"DL Wagner","year":"2021","unstructured":"Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, et al. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021;18:379\u201393.","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"1541_CR235","doi-asserted-by":"crossref","first-page":"13050","DOI":"10.3390\/ijms232113050","volume":"23","author":"V Schirrmacher","year":"2022","unstructured":"Schirrmacher V, van Gool S, Stuecker W. counteracting immunosuppression in the tumor microenvironment by oncolytic newcastle disease virus and cellular immunotherapy. Int J Mol Sci. 2022;23(21):13050.","journal-title":"Int J Mol Sci"},{"key":"1541_CR236","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.vaccine.2010.12.005","volume":"29","author":"J Ni","year":"2011","unstructured":"Ni J, Galani IE, Cerwenka A, Schirrmacher V, Fournier P. Antitumor vaccination by newcastle disease virus hemagglutinin-neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity. Vaccine. 2011;29:1185\u201393.","journal-title":"Vaccine"},{"issue":"12","key":"1541_CR237","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.3390\/cancers12123552","volume":"12","author":"B Burman","year":"2020","unstructured":"Burman B, Pesci G, Zamarin D. Newcastle disease virus at the forefront of cancer immunotherapy. Cancers. 2020;12(12):3552.","journal-title":"Cancers"},{"issue":"10","key":"1541_CR238","doi-asserted-by":"crossref","first-page":"e20230053","DOI":"10.1084\/jem.20230053","volume":"220","author":"K DePeaux","year":"2023","unstructured":"DePeaux K, Rivadeneira DB, Lontos K, Dean VG, Gunn WG, Watson MJ, Yao T, Wilfahrt D, Hinck C, Wieteska L, et al. An oncolytic virus-delivered TGF\u03b2 inhibitor overcomes the immunosuppressive tumor microenvironment. J Exp Med. 2023;220(10):e20230053.","journal-title":"J Exp Med"},{"key":"1541_CR239","doi-asserted-by":"crossref","first-page":"v271","DOI":"10.1093\/annonc\/mdz247.037","volume":"30","author":"R Garcia-Carbonero","year":"2019","unstructured":"Garcia-Carbonero R, Gil Mart\u00edn M, Alvarez Gallego R, Macarulla Mercade T, Riesco Martinez MC, Guillen-Ponce C, Vidal N, Real FX, Moreno R, Maliandi V, et al. 710P - Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: first-in-human clinical trial. Ann Oncol. 2019;30:v271\u20132.","journal-title":"Ann Oncol"},{"key":"1541_CR240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omto.2021.05.009","volume":"22","author":"M Farrera-Sal","year":"2021","unstructured":"Farrera-Sal M, Moreno R, Mato-Berciano A, Maliandi MV, Bazan-Peregrino M, Alemany R. Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation. Mol Ther Oncolytics. 2021;22:27\u201335.","journal-title":"Mol Ther Oncolytics"},{"key":"1541_CR241","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008431","author":"S Wang","year":"2024","unstructured":"Wang S, Li Y, Xu C, Dong J, Wei J. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-008431.","journal-title":"J Immunother Cancer"},{"key":"1541_CR242","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1158\/0008-5472.CAN-21-0052","volume":"81","author":"A Chekaoui","year":"2021","unstructured":"Chekaoui A, Ertl HCJ. PPAR\u03b1 agonist fenofibrate enhances cancer vaccine efficacy. Cancer Res. 2021;81:4431\u201340.","journal-title":"Cancer Res"},{"key":"1541_CR243","doi-asserted-by":"crossref","first-page":"100744","DOI":"10.1016\/j.omto.2023.100744","volume":"31","author":"M Hasanpourghadi","year":"2023","unstructured":"Hasanpourghadi M, Chekaoui A, Kurian S, Kurupati R, Ambrose R, Giles-Davis W, Saha A, Xiaowei X, Ertl HCJ. Treatment with the PPAR\u03b1 agonist fenofibrate improves the efficacy of CD8. Mol Ther Oncolytics. 2023;31:100744.","journal-title":"Mol Ther Oncolytics"},{"issue":"15","key":"1541_CR244","doi-asserted-by":"crossref","first-page":"8035","DOI":"10.3390\/ijms22158035","volume":"22","author":"CG Kim","year":"2021","unstructured":"Kim CG, Sang YB, Lee JH, Chon HJ. Combining cancer vaccines with immunotherapy: establishing a new immunological approach. Int J Mol Sci. 2021;22(15):8035.","journal-title":"Int J Mol Sci"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01541-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01541-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01541-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:49:58Z","timestamp":1764917398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01541-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,25]]},"references-count":244,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01541-7","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,25]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author L.K., V.C., and S.P. are employees and\/or shareholders in Valo Therapeutics. The work was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"24"}}